Core Viewpoint - Elysium Biotech (01061) shares rose over 10%, currently up 9.39% at HKD 5.94, with a trading volume of HKD 9.3261 million following the announcement of a joint development licensing agreement with Shanghai Junshi Biosciences Co., Ltd. [1] Group 1 - The joint development licensing agreement involves Elysium's wholly-owned subsidiaries and Junshi Biosciences for the co-development of licensed products [1] - The licensed product is a recombinant anti-VEGF humanized monoclonal antibody intended for the treatment of wet age-related macular degeneration (wet AMD) [1] - The biological product application for HLX04-O, an anti-VEGF ocular injection, has recently been accepted by the National Medical Products Administration (NMPA) of China [1] Group 2 - HLX04-O is developed based on Junshi's independently developed Hanbeitai (Bevacizumab injection), optimized for ophthalmic use while maintaining the active ingredient [1] - The new ophthalmic formulation is aimed at treating wet AMD, with adjustments made to the prescription, specifications, and production process [1]
港股异动 | 亿胜生物科技(01061)涨超10% anti-VEGF眼用注射生物药品的生物制品许可申请已获受理